Loading
A phase 1/2 trial of Temozolomide in melanoma and prostate cancer, run by Sapience Therapeutics, active and no longer recruiting.
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04478279 by Sapience Therapeutics, with 125 participants enrolled, started 2020-07-01 and due to reach its primary completion in 2026-12. Interventions recorded: ST101, Temozolomide, Radiation. Conditions listed: Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Shares Temozolomide, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/